ReviewCurrent pharmaceutical design2015
siRNA Delivery by Stimuli-Sensitive Nanocarriers.
Review in Current pharmaceutical design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.Therapeutic delivery · 2024Review
- The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Macrophage membrane- and cRGD-functionalized thermosensitive liposomes combined with CPP to realize precise siRNA delivery into tumor cells.Molecular therapy. Nucleic acids · 2022Article
- Laser enhancement of cancer cell destruction by photothermal therapy conjugated glutathione (GSH)-coated small-sized gold nanoparticles.Lasers in medical science · 2021Article
- Photoactivation of sulfonated polyplexes enables localized gene silencing by DsiRNA in breast cancer cells.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Integration of Polylactide into Polyethylenimine Facilitates the Safe and Effective Intracellular siRNA Delivery.Polymers · 2020Article
- siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection.Virusdisease · 2019Article
- Non-viral Delivery of Nucleic Acids: Insight Into Mechanisms of Overcoming Intracellular Barriers.Frontiers in pharmacology · 2018Review
- Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer.Cellular and molecular gastroenterology and hepatology · 2018Article
- Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.International journal of nanomedicine · 2018Article
- Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy.Nature communications · 2017Article
- Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer.Nanomaterials (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Since its discovery in the late 1990, small interfering RNA (siRNA) have quickly crept into the biopharmaceutical research as a new and powerful tool for the treatment of different human diseases based on altered gene-expression. Despite promising data from many pre-clinical studies, concrete hurdles still need to be overcome to bring therapeutic siRNAs in clinic. The design of stimuli-sensitive nanopreparations for gene therapy is a lively area of the current research. Compared to conventional systems for siRNA delivery, this type of platform can respond to local stimuli that are characteristics of the pathological area of interest, allowing the release of nucleic acids at the desired site. Acidic pH, de-regulated levels of enzymes, altered redox potential and magnetic field are examples of stimuli exploit to design stimuli-sensitive nanoparticles. In this review, we discuss on recent stimulisensitive strategies for siRNA delivery and we highlight on the potential of combining multiple stimuli-sensitive strategies in the same nano-platform for a better therapeutic outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.